SCHEMBL3866552

SCHEMBL3866552

O=C(Nc1ccccc1C(=O)Nc1n[nH]c2sc(C(=O)O)cc12)c1cscn1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM4 Q14833 2/20 0.42
PIM1 P11309 1/20 0.41
ADORA3 P0DMS8 1/20 0.39
GRM1 Q13255 1/20 0.39
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
NPSR1 Q6W5P4 1/20 0.36
NPC1 O15118 1/20 0.36
ALDH1A1 P00352 1/20 0.36
TP53 P04637 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C9 P11712 1/20 0.36
HPGD P15428 1/20 0.36
RAB9A P51151 1/20 0.36
FGFR4 P22455 3/20 0.36
BDKRB1 P46663 2/20 0.36
MAPK10 P53779 1/20 0.35
KDM4E B2RXH2 1/20 0.34
GFER P55789 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1778864 0.87 AURKA (0.41) GRM4PIM1ADORA3GRM1NPSR1
SCHEMBL3866786 0.85 KDM4E (0.48) MEN1KMT2ANPSR1NPC1ALDH1A1
SCHEMBL3866073 0.83 HPGD (0.42) ADORA3MEN1KMT2ANPSR1NPC1
SCHEMBL3869683 0.83 FGFR4 (0.40) MEN1KMT2ASMN1; SMN2NPC1RAB9A
SCHEMBL3872653 0.83 ALDH1A1 (0.43) MEN1KMT2AALDH1A1TP53HPGD
SCHEMBL3870804 0.83 NPC1 (0.45) MEN1KMT2ASMN1; SMN2NPC1ALDH1A1
SCHEMBL3868202 0.83 NPSR1 (0.41) MEN1KMT2ANPSR1ALDH1A1HPGD
SCHEMBL3866586 0.83 POLB (0.42) MEN1KMT2ASMN1; SMN2NPSR1NPC1
SCHEMBL3869847 0.82 MAPK1 (0.49) MEN1KMT2ASMN1; SMN2NPSR1NPC1
SCHEMBL4633630 0.81 CA1 (0.48) GRM4ADORA3MEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1904503-B1 1H-THIENO[2,3-C]-PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2013-11-06 EP disclosed
US-20090149457-A1 1H-Thieno[2,3-c]Pyrazole Compounds Useful as Kinase Inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2009-06-11 US disclosed
EP-1904503-A1 1H-THIENO[2,3-C]-PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.r.l. (IT) 2008-04-02 EP disclosed
WO-2007009898-A1 1H-THIENO[2,3-C]PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2007-01-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149457-A1 1H-Thieno[2,3-c]Pyrazole Compounds Useful as Kinase Inhibitors CCNH, PDK1, MAP3K5 GRM4 2485/4885PIM1 230/4885ADORA3 1752/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.